<DOC>
	<DOCNO>NCT02545959</DOCNO>
	<brief_summary>The goal investigator study kinetics action single dose intrathecally-infused rituximab upon cerebro-spinal fluid ( CSF ) biological target progressive MS patient . Various marker central nervous system inflammation ( osteopontin , Tumor Necrosis Factor α , IgG secretion ) neurodegeneration ( neurofilament ) study multiple time-points , assume definitive action upon CSF biological target would strongly predictive delayed clinical action .</brief_summary>
	<brief_title>Intrathecal Rituximab Progressive Multiple Sclerosis</brief_title>
	<detailed_description>• Background : Multiple sclerosis ( MS ) frequent inflammatory disorder lead impairment young people . Although many drug available treat early relapsing-remitting phase MS ( RR-MS ) , impairment mostly link secondary progressive phase MS . Since treatment prove efficiently prevent cure progressive phase , treat phase remain challenge . In fact , progressive phase associate fence-ringed intrathecal compartmentalization inflammation , lead unavailability immunosuppressive drug . As consequence , investigator propose shift therapeutic paradigm MS new paradigm base intrathecal infusion monoclonal antibody ( mAb ) aim eradicate intrathecal inflammation . Rituximab mAb target CD20+ B-lymphocytes . Positive result RR-MS obtained blood infusion rituximab , result negative progressive MS , probably due low penetration blood brain barrier . Since intrathecal rituximab already used central nervous system ( CNS ) lymphoma , investigator propose use way progressive MS. • Detailed description : An optimal dosage rituximab intrathecal infusion choose use data already obtain CNS lymphoma , acknowledge 20mg offer high dosage good tolerance profile . In order isolate rituximab effect , control group treat steroid since steroid require rituximab infusion . Moreover , B-lymphocytes depletion CSF probably transient , rituximab infuse blood . Assuming CSF B-cells repopulation may facilitate peripheral B-cells , group assign receive also blood infusion rituximab . CSF examine multiple time point assess time frame biological effect obtain CSF . Three group 4 patient treat day 0 : 1 . Control group : receive single pulse intravenous ( IV ) methylprednisolone ( 120mg ) ; 2 . Rituximab intrathecal ( IT ) group : receive single intrathecal infusion rituximab ( IV methylprednisolone 120mg avoid side effect ) ; 3 . Rituximab IT + IV group : receive previous IV rituximab ( 375mg/m2 ) day . CSF blood drawn study day 0 ( treatment ) , day 4 , day 21 day 180 . B- lymphocyte monitor blood also do day 365 . A detailed clinical monitoring ( walking time , nine hole peg test , Expanded Disability Status Score ( EDSS ) , Symbol Digit Modalities Test ( SDMT ) , fatigue intensity scale ) do time point day 0 365 , assess tolerance clinical effect . MRI do screening , month 6 12 . - Primary outcome : Change baseline Osteopontin level CSF day 4 . CSF level expect normalize . - Secondary outcome : Biological outcome CSF ( IgG synthesis , Tumor Necrosis Factor α , neurofilament ) day 4 ; delay regain pre-therapeutic level biological target CSF ( day 21 , day 180 ) ; clinical data ( walk time , nine hole peg test , Expanded Disability Status Score ( EDSS ) , Symbol Digit Modalities Test ( SDMT ) , fatigue intensity scale ) time point , brain MRI volumetry day 180 day 365 . - Study design : monocentric prospective randomize open clinical trial ( phase II ) . - Eligibility criterion : Inclusion criterion : - Age ≥45 year , - male female ; - Secondary primary progressive MS , progressive phase since &gt; 2 year ; - EDSS ≥6.0 ; - Absence alternative therapy . Exclusion criterion : - Relapsing-remitting phase MS ; - Contraindication MRI , lumbar puncture , Trendelenburg position ; - Active infection immunosuppressive state treatment ( actual less 6 month ) ; - Earlier treatment rituximab ; - Dementia severe psychiatric disorder . - Arm number label arm type : experimental = Rituximab IT Rituximab IT + IV group ; comparator = Control group ( methylprednisolone ) . - Interventions : Three group 4 patient treat day 0 : 1 ) Control group : receive single pulse IV methylprednisolone ( 120mg ) ; 2 ) Rituximab IT group : receive single intrathecal infusion rituximab ( IV methylprednisolone 120mg avoid side effect ) ; 3 ) Rituximab IT + IV group : receive previous IV rituximab ( 375mg/m2 ) day . - Number subject : 4 per group , total 12 patient . - Statistical analysis : target sample size estimate base expect outcome complete clearance intrathecal inflammation CNS compartment , expect normalize biological marker CSF inflammation . The estimated size 6.8 treatment group 3.4 control group . We decide include respectively 8 4 patient treatment control group . Analyses perform 0.05 global level significance , risk alpha = 0.05 risk beta = 0.10 . We use SAS 9.1.3 software .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age ≥45 year , male female ; Secondary primary progressive MS , progressive phase since &gt; 2 year ; EDSS ≥6.0 ; Absence alternative therapy . Relapsingremitting phase MS ; Contraindication MRI , lumbar puncture , Trendelenburg position ; Active infection immunosuppressive state treatment ( actual less 6 month ) ; Earlier treatment rituximab ; Dementia severe psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Intrathecal Rituximab</keyword>
	<keyword>intrathecal chemotherapy</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>lumbar puncture</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Rituximab</keyword>
</DOC>